12:00 AM
 | 
Jul 15, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Revlimid lenalidomide: Phase III data

The open-label, international Phase III FIRST (MM-020/IFM 07-01) trial in 1,623 patients with newly diagnosed MM who were ineligible for autologous stem cell transplantation (ASCT) showed that continuous oral Revlimid plus low-dose dexamethasone until disease progression met the primary endpoint of improving median PFS vs. a combination of melphalan, prednisone...

Read the full 230 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >